Advertisement

Clinical Drug Investigation

, Volume 32, Supplement 2, pp 15–23 | Cite as

Current Status of Hepatocellular Carcinoma Treatment in Japan

Hepatic Arterial Infusion Chemotherapy
  • Tatsuya YamashitaEmail author
Review Article

Abstract

Hepatic arterial infusion chemotherapy (HAIC) allows the long-term administration of cytotoxic drugs to the liver. In Japan, HAIC has traditionally been used to treat patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or multiple intrahepatic lesions, or both. The most common chemotherapy drugs used for HAIC in Japan are 5-fluorouracil and cisplatin.

Although HAIC is associated with a high rate of response in some studies, it is not associated with a survival benefit. Furthermore, HAIC is associated with complications that are not observed with systemic chemotherapy, including peptic ulcer, arterial occlusion and port infection.

A molecular targeted agent, sorafenib, recently became the standard therapy for advanced HCC on the basis of data from two randomized controlled trials. For this reason, the position of HAIC in the treatment of advanced HCC in Japan is under discussion. Clinical trials must be undertaken to establish standardized protocols and regimens for HAIC, and to determine the efficacy of HAIC in comparison with other therapies for HCC. Without evidence from such trials, HAIC may not find an established role in the treatment of HCC, and may even fall out of use.

Recent evidence suggests that HAIC may be useful in combination with molecular targeted therapy; this is currently being investigated in a number of clinical trials.

Keywords

Sorafenib Tace Primary Liver Cancer Infusion Chemotherapy Hepatic Arterial Infusion Chemothe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25(3): 439–52PubMedCrossRefGoogle Scholar
  2. 2.
    Ganeshan A, Upponi S, Hon LQ, et al. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008; 19(5): 847–51PubMedCrossRefGoogle Scholar
  3. 3.
    Ikai I, Itai Y, Okita K, et al. Report of the 15th Follow-up Survey of Primary Liver Cancer. Hepatol Res 2004; 28(1): 21–9PubMedCrossRefGoogle Scholar
  4. 4.
    Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12(5): 828–9PubMedGoogle Scholar
  5. 5.
    Ikai I, Arii S, Ichida T, et al. Report of the 16th Follow-up Survey of Primary Liver Cancer. Hepatol Res 2005; 32(3): 163–72PubMedCrossRefGoogle Scholar
  6. 6.
    Ikai I, Arii S, Okazaki M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37(9): 676–91PubMedCrossRefGoogle Scholar
  7. 7.
    Ikai I, Kudo M, Arii S, et al. Report of the 18th Follow-up Survey of Primary Liver Cancer in Japan. Hepatology Research 2010; 40(11): 1043–59CrossRefGoogle Scholar
  8. 8.
    Yoshio Y, Shigeki A, Kyoichi I, et al. Survey and follow-up study of primary liver cancer in Japan. Report 14. Acta Hepatologica Japonica 2000; 41(12): 799–811CrossRefGoogle Scholar
  9. 9.
    The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Treatment algorithm for hepatocellular carcinoma. Hepatology Research 2010; 40 Suppl. 1: 8–9Google Scholar
  10. 10.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399): 1907–17PubMedCrossRefGoogle Scholar
  11. 11.
    Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma: an update [online]. Available from URL: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf [Accessed 2011 Jan 25]
  12. 12.
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers V.2.2012 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed 2012 Feb 09]
  13. 13.
    The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Chapter 4: Chemotherapy and radiotherapy. Hepatology Research 2010; 40 Suppl. 1: 74–95Google Scholar
  14. 14.
    Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, et al. Intra-arterial versus systemic chemotherapy for nonoperable hepatocellular carcinoma. Hepatogastroenterology 1999; 46(26): 1122–5PubMedGoogle Scholar
  15. 15.
    Kudo M, Arii S, Ikai I, et al. Report of the 17th Follow-up Survey of Primary Liver Cancer (in Japanese). Kyoto: Media Planning, 2006Google Scholar
  16. 16.
    Yamaoka Y, Ikai I, Itai Y, et al. Liver Cancer Study Group Japan. Survey and follow-up study of primary liver cancer in Japan — Report 15 (in Japanese). Kanzo 2003; 44: 157–75CrossRefGoogle Scholar
  17. 17.
    Yamaoka Y, Arii S, Inoue K, et al. Liver Cancer Study Group of Japan Survey and follow-up study of primary liver cancer in Japan — Report 14 (in Japanese). Kanzo 2000; 41: 799–811CrossRefGoogle Scholar
  18. 18.
    Yamaoka Y, Ikai I, Arii S, et al. Liver Cancer Study Group of Japan. Report of the 16th Follow-up Survey of Primary Liver Cancer (2000–2001) (in Japanese). Kanzo 2005; 46: 234–54CrossRefGoogle Scholar
  19. 19.
    Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78 Suppl. 1: 148–53PubMedCrossRefGoogle Scholar
  20. 20.
    Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95(3): 588–95PubMedCrossRefGoogle Scholar
  21. 21.
    Eun JR, Lee HJ, Moon HJ, et al. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44(12): 1477–86PubMedCrossRefGoogle Scholar
  22. 22.
    Lai YC, Shih CY, Jeng CM, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9(12): 2666–70PubMedGoogle Scholar
  23. 23.
    Naganuma A, Toyoda M, Hamada T, et al. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. Gan To Kagaku Ryoho 2007; 34(5): 729–34PubMedGoogle Scholar
  24. 24.
    Okuda K, Tanaka M, Shibata J, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6(3): 587–91PubMedGoogle Scholar
  25. 25.
    Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110(1): 129–37PubMedCrossRefGoogle Scholar
  26. 26.
    Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003; 181(5): 1327–34PubMedCrossRefGoogle Scholar
  27. 27.
    Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23(2C): 1891–7PubMedGoogle Scholar
  28. 28.
    Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 137(4): 659–67 [Epub 2010 Jun 16]PubMedCrossRefGoogle Scholar
  29. 29.
    Cheong JY, Lee KM, Cho SW, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2005; 32(2): 127–33PubMedCrossRefGoogle Scholar
  30. 30.
    Murata K, Shiraki K, Kawakita T, et al. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003; 23(2C): 1719–22PubMedGoogle Scholar
  31. 31.
    Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40(1): 70–8PubMedCrossRefGoogle Scholar
  32. 32.
    Yamasaki T, Kurokawa F, Takami T, et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27(1): 36–44PubMedCrossRefGoogle Scholar
  33. 33.
    Nagamatsu H, Hiraki M, Mizukami N, et al. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 2010; 32(4): 543–50PubMedCrossRefGoogle Scholar
  34. 34.
    Enjoji M, Morizono S, Kotoh K, et al. Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005; 11(36): 5685–7PubMedGoogle Scholar
  35. 35.
    Hirooka M, Koizumi Y, Kisaka Y, et al. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. AJR Am J Roentgenol 2010; 194(2): W221–6PubMedCrossRefGoogle Scholar
  36. 36.
    Kuroda M, Kobayashi Y, Urawa N, et al. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. Hepatogastroenterology 2007; 54(74): 518–21PubMedGoogle Scholar
  37. 37.
    Nagano H, Miyamoto A, Wada H, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007; 110(11): 2493–501PubMedCrossRefGoogle Scholar
  38. 38.
    Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106(9): 1990–7PubMedCrossRefGoogle Scholar
  39. 39.
    Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93(5): 557–64PubMedCrossRefGoogle Scholar
  40. 40.
    Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94(2): 435–42PubMedCrossRefGoogle Scholar
  41. 41.
    Uka K, Aikata H, Takaki S, et al. Similar effects of recombinant interferon-alpha-2b and natural interferonalpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27(9): 1209–16PubMedGoogle Scholar
  42. 42.
    Uka K, Aikata H, Takaki S, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42(10): 845–53PubMedCrossRefGoogle Scholar
  43. 43.
    Baba H, Matsumoto G, Tsuruta K, et al. [Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma]. Gan To Kagaku Ryoho 2004; 31(11): 1705–7PubMedGoogle Scholar
  44. 44.
    Carr BI, Dvorchik I. Effects of cisplatin dose intensity on response and survival for patients with unresectable and untransplantable hepatocellular carcinoma: an analysis of 57 patients. Gan To Kagaku Ryoho 2000; 27 Suppl. 2: 432–5PubMedGoogle Scholar
  45. 45.
    Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88(9): 1986–91PubMedCrossRefGoogle Scholar
  46. 46.
    Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20(5–6): 613–25PubMedCrossRefGoogle Scholar
  47. 47.
    Kajanti M, Rissanen P, Virkkunen P, et al. Regional intraarterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer 1986; 58(11): 2386–8PubMedCrossRefGoogle Scholar
  48. 48.
    Yoshikawa M, Ono N, Yodono H, et al. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008; 38(5): 474–83PubMedCrossRefGoogle Scholar
  49. 49.
    Yamashita YI, Taketomi A, Itoh S, et al. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call(®) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 65(2): 301–7CrossRefGoogle Scholar
  50. 50.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–90PubMedCrossRefGoogle Scholar
  51. 51.
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34PubMedCrossRefGoogle Scholar
  52. 52.
    Bayer. Nexavar approved in Japan for the treatment of advanced liver cancer [online]. Available from URL: http://www.onyx-pharm.com/view.cfm/589/Nexavar-Approved-in-Japan-for-the-Treatment-of-Advanced-Liver-Cancer. [Accessed 2011 Jan 25]
  53. 53.
    Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99(1): 159–65PubMedGoogle Scholar
  54. 54.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205–16PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  1. 1.Department of GastroenterologyKanazawa University HospitalKanazawa, IshikawaJapan

Personalised recommendations